Entyvio market forecast points to steady growth through 2035

The global Entyvio market is set to expand as inflammatory bowel disease cases rise, biologic therapy adoption deepens, and healthcare spending climbs. North America leads now, while Asia-Pacific is expected to grow fastest as access and awareness improve.

Why it matters: - Rising inflammatory bowel disease cases are expanding the patient pool for Entyvio, a biologic used to treat ulcerative colitis and Crohn’s disease. - The market’s growth matters because Entyvio offers a gut-targeted alternative to broader immunosuppressants, which can shape treatment choices and long-term care plans. - Higher healthcare spending can make advanced biologic therapies more available to more patients.

What happened: - The Business Research Company published its Entyvio Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Entyvio market is positioned for notable growth through the forecast period. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region in the coming years.

The details: - Entyvio, also known as vedolizumab, is a monoclonal antibody that blocks integrin receptors. - The drug prevents inflammatory white blood cells from migrating into the gastrointestinal tract, reducing inflammation tied to IBD. - Growth over recent years has been driven by the limits of traditional immunosuppressive treatments, increasing IBD cases, positive clinical results, broader use by gastroenterologists, and regulatory approvals for ulcerative colitis and Crohn’s disease. - Future growth is expected to come from rising global IBD prevalence, earlier use of Entyvio in treatment, better diagnostics, improved access to biologics, and a stronger focus on long-term disease management. - The report flags several forecast-period trends: greater use of gut-selective biologics, wider application in moderate to severe IBD, stronger preference for targeted integrin inhibitors, more long-term maintenance therapy, and a greater emphasis on safety versus systemic immunosuppressants. - The U.S. Centers for Disease Control and Prevention estimated in June 2024 that 2.4 million to 3.1 million people in the United States live with IBD. - The UK Office for National Statistics reported in May 2023 that healthcare spending rose 5.6% from 2022 to 2023, reaching about $317.63 billion (£292 billion). - The report covers North America, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - A free sample is available through the sample request page. - The full report is available at the company’s report page.

Between the lines: - The report frames Entyvio as part of a broader shift toward targeted biologics in inflammatory disease care. - Faster growth in Asia-Pacific suggests the market opportunity may be increasingly tied to healthcare access and diagnosis rates, not just disease burden. - The added analytics tools in the report signal a sales and strategy focus for buyers tracking market sizing and competitive positioning.

What's next: - The market’s growth path will likely depend on how quickly earlier diagnosis, broader reimbursement, and biologic access expand across regions. - Longer-term adoption may hinge on whether safety-focused treatment strategies continue to favor gut-selective therapies over broader immunosuppressive options. - The report’s forecast period runs through 2035.